AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7440192
Drug: Heparin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (2 x 5000 IU/day) + 0.5 mg dihydroergot (DHE)
Trial: 21078382
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of arsenic
Trial: 12195131
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg three times daily
Trial: 9425508
Drug: Continuous risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous risedronate 2.5 mg
Trial: 9425508
Drug: Cyclic risedronate
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic risedronate 2.5 mg
Trial: 8345499
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg verapamil
Trial: 8503714
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs simultaneously
Trial: 3620826
Drug: Hexabrix (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexabrix (320 mg iodine/ml)
Trial: 3620826
Drug: Iopamiron (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamiron (300 mg iodine/ml)
Trial: 3620826
Drug: iohexol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol (300 mg iodine/ml)
Trial: 27302000
Drug: Fractionated propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fractionated propofol administration (FPA)
Trial: 12163917
Drug: Amodiaquine (AQ)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine (AQ) - 30 mg/kg body weight in three divided daily doses
Trial: 12163917
Drug: Sulfadoxine-pyrimethamine (SP)
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (SP) - 25 mg/kg body weight of sulfadoxine and 1.25 mg/kg of pyrimethamine in a single oral dose
Trial: 12163917
Drug: Sulfadoxine-pyrimethamine-amodiaquine combination
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine-amodiaquine combination (SP+AQ) - same doses as in SP and AQ, given simultaneously on day 0
Trial: 2328557
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day fluoxetine
Trial: 2328557
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day fluoxetine
Trial: 25580087
Drug: Dobutamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine treatment to maintain StO2 ≥ 80%
Trial: 25580087
Drug: Dobutamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine treatment
Trial: 20386555
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment arm
Trial: 20386555
Drug: Steroids before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids before study entry
Trial: 18339790
Drug: Inhaled mannitol
RxNorm normalized name: mannitol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled mannitol (420 mg, twice daily for 2 weeks)
Trial: 15975155
Drug: Glucose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (50 g carbohydrate drink)
Trial: 15975155
Drug: Sucrose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (50 g carbohydrate drink)
Trial: 6134626
Drug: Water (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (300 ml)
Trial: 15975155
Drug: Fructose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (50 g carbohydrate drink)
Trial: 8785133
Drug: morphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.15 mg kg‐1 i.v. at peritoneal closure after hysterectomy (group post)
Trial: 8785133
Drug: morphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.15 mg kg‐1 on induction of anaesthesia (group pre‐low)
Trial: 8785133
Drug: morphine 0.3
RxNorm normalized name: ethylmorphine 0.32 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.3 mg kg‐1 on induction of anaesthesia (group pre‐high)
Trial: 8785133
Drug: morphine 0.3
RxNorm normalized name: ethylmorphine 0.32 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.3 mg kg‐1 i.v. on induction of anaesthesia (group pre‐high)
Trial: 6387754
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment by their doctor (Control)
Trial: 28415135
Drug: Enteral feeding
RxNorm normalized name: enteral feeding dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral feeding improvement massage (twice a day for 14 days)
Trial: 26419096
Drug: ORS group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS group (1,500 ml ORS 6 to 2 hours before anesthesia)
Trial: 12012316
Drug: All‐trans retinoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All‐trans retinoic acid (ATRA) and anthracycline‐based chemotherapy
Trial: 10713869
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metoclopramide 150 micrograms kg‐1 and ondansetron 100 micrograms kg‐1
Trial: 6384161
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sensitizers (misonidazole and hyperbaric oxygen)
Trial: 30840831
Drug: Leucocyte-rich platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte-rich platelet-rich plasma (LR-PRP) injection
Trial: 29763594
Drug: Intravenous Patient-Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Patient-Controlled Analgesia (PCA)
Trial: 11288047
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (NA) 7.4 mg.kg(‐1) body weight before exercise and 3.7 mg.kg(‐1) at 0 and 30 minutes of exercise
Trial: 9237962
Drug: Olestra 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra 0 g/d
Trial: 9237962
Drug: Olestra 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra 8 g/d
Trial: 9237962
Drug: Olestra 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra 20 g/d
Trial: 9237962
Drug: Olestra 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra 32 g/d
Trial: 2754630
Drug: Nortriptyline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline treatment
Trial: 29948822
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg TNK‐tPA
Trial: 29948822
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg TNK‐tPA
Trial: 17228023
Drug: Adjuvant fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant fluorouracil (FU) treatment
Trial: 7875113
Drug: Bilateral electroconvulsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral electroconvulsive therapy (ECT)
Trial: 7931862
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus Training and Employment Program (TEP)
Trial: 7931862
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus TEP
Trial: 2967089
Drug: Intravenous 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 7.5 mg dose of SQ 27, 519
Trial: 2967089
Drug: Oral 10
RxNorm normalized name: Syringe Oral 10cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 10 mg doses of fosinopril sodium (capsule and solution)
Trial: 2967089
Drug: Oral doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of fosinopril sodium
Trial: 25944453
Drug: Rapid diagnosis
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid diagnosis and treatment of IS
Trial: 25944453
Drug: Early diagnosis
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early diagnosis and treatment
Trial: 20185602
Drug: QW dosing
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QW dosing of epoetin alfa
Trial: 20185602
Drug: Q2W dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q2W dosing of epoetin alfa
Trial: 20185602
Drug: Q4W dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q4W dosing of epoetin alfa
Trial: 18237394
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (200,000 IU) plus zinc (10 mg elemental zinc, six days a week)
Trial: 16730929
Drug: EPT (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPT (1 mg 17beta‐estradiol + 0.5 mg NETA)
Trial: 14650366
Drug: nifuratel 125
RxNorm normalized name: nifuratel
DrugBank: Nifuratel (DB13724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifuratel 125 mg/nystatin 50000 IU
Trial: 14650366
Drug: nifuratel 250
RxNorm normalized name: nifuratel 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifuratel 250 mg/nystatin 100000 IU
Trial: 14650366
Drug: nifuratel 500
RxNorm normalized name: nifuratel
DrugBank: Nifuratel (DB13724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifuratel 500 mg/nystatin 200000 IU
Trial: 10736141
Drug: Iontophoresis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis of a topical solution of 2% lidocaine with epinephrine 1:100,000
Trial: 10736141
Drug: 2.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% lidocaine and 2.5% prilocaine (EMLA cream)
Trial: 3157720
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline (NT) with cognitive therapy
Trial: 29702652
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of H10407 at a dose of 105 CFU
Trial: 29702652
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of H10407 at a dose of 106 CFU
Trial: 23074170
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment at a dose of 0.1 IU/kg/day for 14 days
Trial: 20567613
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic and steroids
Trial: 8580280
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg q.d.s. for 1 week
Trial: 8580280
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg t.d.s. for 1 week
Trial: 31129370
Drug: Sequential multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential multiple assignment randomization trial (SMART) design
Trial: 16739844
Drug: Governor Vessel
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Governor Vessel Daoqi needling method combined with antidepressants
Trial: 16739844
Drug: Simple antidepressants
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple antidepressants
Trial: 7640145
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan 100 mg
Trial: 9051333
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference for injection
Trial: 9051333
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral and subcutaneous sumatriptan
Trial: 8377981
Drug: Tinidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (2 g single oral dose) for women and their partners
Trial: 8377981
Drug: Tinidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (2 g single oral dose) for women
Trial: 3803198
Drug: Oral tilidine
RxNorm normalized name: tilidine
DrugBank: Tilidine (DB13787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tilidine
Trial: 3803198
Drug: Intramuscular tilidine
RxNorm normalized name: tilidine
DrugBank: Tilidine (DB13787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular tilidine
Trial: 7485932
Drug: Parenteral morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral morphine
Trial: 3384584
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 200 mg dl‐alpha‐tocopheryl acetate
Trial: 28303587
Drug: AMX +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMX + 250 mg of MTZ for 14 days
Trial: 28303587
Drug: AMX +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMX + 400 mg of MTZ for 14 days
Trial: 28303587
Drug: 250 or
RxNorm normalized name: Urso-250 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 or 400 mg of MTZ for 7 days
Trial: 26964159
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group (cetirizine)
Trial: 21284065
Drug: Acceptance-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based behavioral therapy
Trial: 19482866
Drug: Cladribine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine (5 mg/day for seven 5-day courses)
Trial: 12740678
Drug: Aceclofenac 2
RxNorm normalized name: Aceclofenac 200 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac 2 x 100 mg daily
Trial: 12740678
Drug: Diclofenac resinate
RxNorm normalized name: cholestyramine resin / diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac resinate 2 x 75 mg daily
Trial: 10699617
Drug: Prolonged combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged combined androgen blockade (CAB) therapy (120 days or more)
Trial: 10699617
Drug: Short-term combined
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term combined androgen blockade (CAB) therapy (less than 120 days)
Trial: 10699617
Drug: Prolonged CAB
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged CAB therapy (120 days or more) in patients who lived at least 2 years
Trial: 9328500
Drug: Acamprosate 1332
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 1332 mg/day
Trial: 9328500
Drug: Acamprosate 1998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 1998 mg/day
Trial: 8229496
Drug: Bacterial polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial polysaccharide immune globulin (BPIG), 0.5 ml/kg, administered intramuscularly at entry and 30 days later.
Trial: 8229496
Drug: Saline placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo, administered intramuscularly at entry and 30 days later.
Trial: 29313180
Drug: Pasireotide subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide subcutaneous treatment (300–600 μg s.c. twice-daily)
Trial: 29313180
Drug: Pasireotide long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide long-acting release (LAR) treatment (40–60 mg monthly)
Trial: 29313180
Drug: Pasireotide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide treatment overall
Trial: 24760537
Drug: Pasireotide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide treatment
Trial: 26708314
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg aspirin daily for up to 24 weeks
Trial: 26708314
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for up to 24 weeks
Trial: 23676420
Drug: Chemoradiotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy after 4 months of chemotherapy
Trial: 23676420
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of chemotherapy
Trial: 19040013
Drug: GIK intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK intravenous infusion for 24 hours plus routine treatment (3739 patients)
Trial: 19040013
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving routine treatment alone (3771 patients)
Trial: 16373887
Drug: Active titration
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active titration with laboratory A1C testing
Trial: 16373887
Drug: Active titration
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active titration with POC A1C testing
Trial: 16373887
Drug: Usual titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual titration with laboratory A1C testing
Trial: 16373887
Drug: Usual titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual titration with POC A1C testing
Trial: 12602372
Drug: Verteporfin +
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin + cold red laser therapy
Trial: 12602372
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + cold red laser therapy
Trial: 2271125
Drug: ORS‐90 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS‐90 (60 mmol/L sodium, 90 mmol/L glucose, osmolality 311 mOsm/kg)
Trial: 2271125
Drug: ORS‐60 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS‐60 (60 mmol/L sodium, 90 mmol/L glucose, osmolality 240 mOsm/kg)
Trial: 7282695
Drug: Written and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written and oral consultation (Group 3)
Trial: 7282695
Drug: Written and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written and oral consultation plus call-back (Group 4)
Trial: 7282695
Drug: Written and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written and oral consultation
Trial: 24445245
Drug: Aripiprazole 1-15
RxNorm normalized name: aripiprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 1-15 mg/day
Trial: 24445245
Drug: Aripiprazole 10-20
RxNorm normalized name: aripiprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10-20 mg/day
Trial: 24445245
Drug: Aripiprazole 15-28.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 15-28.1 mg/day
Trial: 19731968
Drug: Aripiprazole 20-30
RxNorm normalized name: aripiprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 20-30 mg/day
Trial: 24445245
Drug: Aripiprazole <10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole <10 mg/day
Trial: 20684264
Drug: New compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New compound codonopsis tablets
Trial: 17885563
Drug: Cilnidipine 10
RxNorm normalized name: Cilnidipine 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine 10 mg once daily for 24 weeks
Trial: 18971536
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg once daily for 24 weeks
Trial: 16036441
Drug: Step-by-step administration
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-by-step administration of the ROCF
Trial: 16036441
Drug: Standard administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard administration of the ROCF
Trial: 12142111
Drug: Sequential pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pacing
Trial: 19808133
Drug: ALN monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN monohydrate 10 mg once daily for 12 weeks
Trial: 16460246
Drug: Identical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical treatment using distilled water as the cooling liquid (control)
Trial: 15255451
Drug: Multivitamin-trace element
RxNorm normalized name: chromic chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multivitamin-trace element supplement
Trial: 11261333
Drug: Optimized uni‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized uni‐ or biventricular pacing therapy
Trial: 9278200
Drug: Aspirin 750
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 750 mg, three times a day for 5 days
Trial: 3804185
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg daily